Moreover, in vitro, si-LINC01857 inhibited both metastasis and angiogenesis of BC cells, and in vivo, we found that si-linc01857 inhibited tumor growth and vascularization, possibly through regulation of miR-2052/CENPQ, providing an experimental basis that LINC01857 potentially served as the novel marker for BC treatment. The gene discussed is CENPQ; the disease is breast cancer.